• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status.

作者信息

Hjortkjær Mette, Kanstrup Hanne, Jakobsen Anders, Steffensen Karina Dahl

机构信息

Department of Oncology, Vejle Hospital, Kabbeltoft 25, DK-7100 Vejle, Denmark; Department of Gynaecology and Obstetrics, Aalborg University Hospital, Reberbansgade, DK-9000 Aalborg, Denmark; Institute of Regional Health Research, University of Southern Denmark, Winsløwparken 19-3, DK-5000 Odense, Denmark; Department of Gynaecology and Obstetrics, Viborg Hospital, Heibergs Allé 4, 8800 Viborg, Denmark.

Department of Oncology, Vejle Hospital, Kabbeltoft 25, DK-7100 Vejle, Denmark.

出版信息

Cancer Treat Res Commun. 2018;14:7-12. doi: 10.1016/j.ctarc.2017.09.001. Epub 2017 Sep 27.

DOI:10.1016/j.ctarc.2017.09.001
PMID:30104007
Abstract
摘要

相似文献

1
Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status.维利帕尼与拓扑替康用于BRCA阴性或BRCA状态未知的铂耐药或部分铂敏感复发性上皮性卵巢癌患者。
Cancer Treat Res Commun. 2018;14:7-12. doi: 10.1016/j.ctarc.2017.09.001. Epub 2017 Sep 27.
2
Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study.维利帕尼单药治疗携带BRCA种系突变以及铂耐药或部分铂敏感复发性上皮性卵巢癌患者：一项I/II期研究。
Int J Gynecol Cancer. 2017 Nov;27(9):1842-1849. doi: 10.1097/IGC.0000000000001089.
3
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.强效、高选择性聚（ADP-核糖）聚合酶（PARP）抑制剂维利帕尼治疗携带种系BRCA1或BRCA2突变的持续性或复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌的II期评估——一项NRG肿瘤学/妇科肿瘤学组研究
Gynecol Oncol. 2015 Jun;137(3):386-91. doi: 10.1016/j.ygyno.2015.03.042. Epub 2015 Mar 24.
4
BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.BRCA1/2 突变与表达：晚期上皮性卵巢癌患者铂类化疗的反应。
Gynecol Oncol. 2012 Jun;125(3):677-82. doi: 10.1016/j.ygyno.2012.03.006. Epub 2012 Mar 8.
5
BRCA mutation carriers suffering from ovarian cancer as a model for treatment decision in higher lines - Place for platinum reinduction.患有卵巢癌的BRCA突变携带者作为高级别治疗决策的模型——铂类再诱导的地位。
J Cancer Res Ther. 2023 Apr-Jun;19(3):684-687. doi: 10.4103/jcrt.jcrt_880_21.
6
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.奥拉帕利维持单药治疗无胚系BRCA1/BRCA2突变的铂敏感复发性卵巢癌患者：OPINION初步分析
Gynecol Oncol. 2022 Mar;164(3):498-504. doi: 10.1016/j.ygyno.2021.12.025. Epub 2022 Jan 19.
7
Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.现行策略在高级别浆液性上皮性卵巢癌的靶向治疗中的应用及 BRCA 突变状态的相关性。
J Ovarian Res. 2019 Jan 28;12(1):9. doi: 10.1186/s13048-019-0484-6.
8
Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer.循环 HOXA9 甲基化肿瘤 DNA：BRCA 突变上皮性卵巢癌对聚（ADP-核糖）聚合酶抑制反应的新型生物标志物。
Eur J Cancer. 2020 Jan;125:121-129. doi: 10.1016/j.ejca.2019.11.012. Epub 2019 Dec 20.
9
Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin.携带BRCA基因突变的卵巢癌患者：腹腔内注射顺铂后预后改善
Ann Surg Oncol. 2014 May;21(5):1468-73. doi: 10.1245/s10434-013-3277-y. Epub 2013 Oct 1.
10
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.GOG 9923 事后分析：BRCA 状态是否影响毒性？：一项 NRG 肿瘤学研究。
Gynecol Oncol. 2021 May;161(2):512-515. doi: 10.1016/j.ygyno.2021.01.037. Epub 2021 Feb 17.

引用本文的文献

1
Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers.人表皮生长因子受体2（HER2）表达或扩增的妇科癌症的诊断与治疗进展
Gynecol Oncol. 2025 Apr;195:152-164. doi: 10.1016/j.ygyno.2025.03.011. Epub 2025 Mar 20.
2
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective.从分子和临床角度概述卵巢癌的 PARP 耐药性。
Int J Mol Sci. 2023 Jul 25;24(15):11890. doi: 10.3390/ijms241511890.
3
Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma.
BADSer99磷酸化和PARP的联合抑制消除复发性卵巢癌模型。
Commun Med (Lond). 2022 Jul 2;2:82. doi: 10.1038/s43856-022-00142-3. eCollection 2022.
4
Perspectives on PARP Inhibitor Combinations for Ovarian Cancer.卵巢癌PARP抑制剂联合治疗的前景
Front Oncol. 2021 Dec 15;11:754524. doi: 10.3389/fonc.2021.754524. eCollection 2021.
5
Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?卵巢癌中新的聚（ADP - 核糖）聚合酶（PARP）抑制剂的研发：路在何方？
Ann Transl Med. 2020 Dec;8(24):1706. doi: 10.21037/atm.2020.03.156.
6
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective.聚（ADP-核糖）聚合酶抑制剂与上皮性卵巢癌：分子机制、临床进展及未来展望
Oncol Lett. 2020 Oct;20(4):90. doi: 10.3892/ol.2020.11951. Epub 2020 Aug 6.
7
Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach.尼拉帕利治疗卵巢癌：一种新的合成致死治疗方法。
Invest New Drugs. 2020 Feb;38(1):181-193. doi: 10.1007/s10637-019-00867-4. Epub 2019 Oct 24.
8
Bioengineered adipose-derived stem cells for targeted enzyme-prodrug therapy of ovarian cancer intraperitoneal metastasis.生物工程脂肪来源的干细胞用于卵巢癌腹腔转移的靶向酶前药治疗。
J Control Release. 2019 Oct;311-312:273-287. doi: 10.1016/j.jconrel.2019.09.006. Epub 2019 Sep 6.
9
Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer.PARP抑制剂在卵巢癌临床试验中的现状与未来前景
Cancer Manag Res. 2019 May 10;11:4371-4390. doi: 10.2147/CMAR.S200524. eCollection 2019.